Characterization of Cyp2d22, a novel cytochrome P450 expressed in mouse mammary cells

被引:30
作者
Blume, N [1 ]
Leonard, J [1 ]
Xu, ZJ [1 ]
Watanabe, O [1 ]
Remotti, H [1 ]
Fishman, J [1 ]
机构
[1] Strang Canc Res Lab, New York, NY 10021 USA
关键词
cytochrome P450; mammary gland; adenovirus; oxidation;
D O I
10.1006/abbi.2000.1978
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Endogenous steroids and numerous environmental agents have potent effects on mammary development and carcinogenesis. Locally produced cytochrome P450 enzymes that modify such molecules are therefore likely to be important regulators of these processes. Here we describe the characterization of a novel mouse gene, termed Cyp2d22, that is highly expressed in the mammary tumor derived cell line RIIII/ Prl. Cyp2d22 is expressed at intermediate levels in the weakly tumorigenic cell line RIII/MG, whereas expression is low or absent in all normal mouse mammary epithelial cell lines tested and three C3H mammary tumor derived cell lines. Immunoblot analysis of mouse tissues with highly specific antisera indicates that 2D22 protein levels are most abundant in liver, while intermediate levels of expression are seen in adrenal, ovary, and mammary gland. Immunohistochemical staining of liver sections with these antisera demonstrates that 2D22 is most abundant in the first layer or two of parenchymal cells surrounding the central vein, with virtually no expression detected in periportal cells. Interestingly, sequence similarity and functional data suggest that Cyp2d22 may be the mouse ortholog of human CYP2D6. These observations support the hypothesis that 2D22 mediates a distinct, biologically significant activity in relation to other mouse 2D family members. (C) 2000 Academic Press.
引用
收藏
页码:191 / 204
页数:14
相关论文
共 56 条
[1]   AROMATIZATION OF ANDROSTENEDIONE BY HUMAN ADIPOSE-TISSUE STROMAL CELLS IN MONOLAYER-CULTURE [J].
ACKERMAN, GE ;
SMITH, ME ;
MENDELSON, CR ;
MACDONALD, PC ;
SIMPSON, ER .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1981, 53 (02) :412-417
[2]   CYP2D6 GENES AND RISK OF LIVER-CANCER [J].
AGUNDEZ, JAG ;
LEDESMA, MC ;
BENITEZ, J ;
LADERO, JM ;
RODRIGUEZLESCURE, A ;
DIAZRUBIO, E ;
DIAZRUBIO, M .
LANCET, 1995, 345 (8953) :830-831
[3]  
Ausubel FM., 1994, Curr. Protoc. Mol. Biol
[4]  
Bouchardy C, 1996, CANCER RES, V56, P251
[5]  
Bradlow HI, 1996, J ENDOCRINOL, V150, pS259
[6]   RELATIONSHIP OF CYP2D6 (DEBRISOQUINE HYDROXYLASE) GENOTYPE TO BREAST-CANCER SUSCEPTIBILITY [J].
BUCHERT, ET ;
WOOSLEY, RL ;
SWAIN, SM ;
OLIVER, SJ ;
COUGHLIN, SS ;
PICKLE, L ;
TROCK, B ;
RIEGEL, AT .
PHARMACOGENETICS, 1993, 3 (06) :322-327
[7]   ZONATION OF CYTOCHROME-P450 ISOZYME EXPRESSION AND INDUCTION IN RAT-LIVER [J].
BUHLER, R ;
LINDROS, KO ;
NORDLING, A ;
JOHANSSON, I ;
INGELMANSUNDBERG, M .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1992, 204 (01) :407-412
[8]   HUMAN CELL-LINES, DERIVED FROM AHH-1 TK+/- HUMAN LYMPHOBLASTS, GENETICALLY-ENGINEERED FOR EXPRESSION OF CYTOCHROMES-P450 [J].
CRESPI, CL ;
LANGENBACH, R ;
PENMAN, BW .
TOXICOLOGY, 1993, 82 (1-3) :89-104
[9]   CYTOCHROME-P450 MEDIATED REACTIONS STUDIED IN GENETICALLY-ENGINEERED V79 CHINESE-HAMSTER CELLS [J].
DOEHMER, J ;
HOLTKAMP, D ;
SOBALLA, V ;
RAAB, G ;
SCHMALIX, W ;
SEIDEL, A ;
GREIM, H ;
JACOB, J .
PHARMACOGENETICS, 1995, 5 :S91-S96
[10]   Combined genetic polymorphism and risk for development of lung cancer [J].
El-Zein, R ;
Zwischenberger, JB ;
Wood, TG ;
Abdel-Rahman, SZ ;
Brekelbaum, C ;
Au, WW .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1997, 381 (02) :189-200